ABI M602
Alternative Names: ABI-M602Latest Information Update: 28 Aug 2024
At a glance
- Originator Assembly Biosciences
- Class Antineoplastics; Bacteria
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Cancer in USA (PO)
- 01 Jul 2020 ABI M602 is available for licensing as of 01 Jul 2020. https://www.assemblybio.com/collaborations/
- 01 Jul 2020 Early research in Cancer in USA (PO) (Assembly Bioscience pipeline, July 2020)